<DOC>
	<DOCNO>NCT01671020</DOCNO>
	<brief_summary>Open-label , randomize , crossover clinical trial single oral dose 60mg fimasartan single IV infusion 30mg fimasartan evaluate absolute bioavailability Kanarb® tablet ( fimasartan ) healthy subject</brief_summary>
	<brief_title>Clinical Trials Single Oral Dose 60mg Fimasartan Single IV Infusion 30mg Fimasartan Evaluate Absolute Bioavailability Kanarb® Tablet ( Fimasartan ) Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>age : 20 55 year body weight : standard weight ( Broca 's index , Possible range plus minus 20percent ) write informed consent know allergy Fimasartan exist cardiac hematological disease exist hepatic renal disease exist gastrointestinal disease acute chronic disease could affect drug absorption metabolism history serious psychological disorder abnormal diet could affect drug absorption metabolism positive drug alcohol screen smoker 10 cigarette per day participation clinical trial last 90 day prior start study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>fimasartan</keyword>
	<keyword>absolute bioavailability</keyword>
</DOC>